IGI Logo

Gland Pharma inches up on getting USFDA’s approval for Angiotensin II Acetate Injection

Jun-04-2025   09:30 Hrs IST

Gland Pharma is currently trading at Rs. 1597.45, up by 3.65 points or 0.23% from its previous closing of Rs. 1593.80 on the BSE.

The scrip opened at Rs. 1593.80 and has touched a high and low of Rs. 1605.00 and Rs. 1592.00 respectively. So far 171 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1200.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1639.00 and Rs. 1515.00 respectively. The current market cap of the company is Rs. 26258.88 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 40.17% and 7.99% respectively.

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Angiotensin II Acetate Injection 2.5 mg/ml. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA of La Jolla Pharma LLC. 

This product is indicated for increasing the blood pressure in adults with septic or other distributive shock. The company is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity. According to IQVIA, the product had US sales of around $58 million for the twelve months ending March 2025.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.